BioPharma Credit (LSE:BPCR) Insider Ownership: 0.08 % (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:BPCR BioPharma Credit PLC LSE:BPCR
51 GF Score
Price $0.97
GF Value $0.96
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BioPharma Credit Insider Ownership?

BioPharma Credit LSE:BPCR +0.21% 51 Insider Ownership is 0.08 % as of Aug. 14, 2026. GuruFocus rates LSE:BPCR with a GF Score™ of 51/100 and a GF Value™ of $0.96 (Fairly Valued). The stock has 2 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BioPharma Credit's insider ownership is 0.08%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BioPharma Credit's Institutional Ownership is 26.59%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BioPharma Credit's Float Percentage Of Total Shares Outstanding is 0.00%.

BioPharma Credit Insider Ownership Historical Data

* Premium members only.

The historical data trend for BioPharma Credit's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioPharma Credit Insider Ownership Chart

BioPharma Credit Historical Data

The historical data trend for BioPharma Credit can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08
LSE:BPCR
51GF Score
BioPharma Credit PLC LSE:BPCR
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioPharma Credit Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.08 % mean?
BioPharma Credit (LSE:BPCR) has a Insider Ownership of 0.08 % as of Aug. 14, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on BioPharma Credit and its competitors.
Is BioPharma Credit's Insider Ownership too high?
BioPharma Credit's current Insider Ownership is 0.08 %. Overall, BioPharma Credit has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's Insider Ownership compare to BLK and BX?
BioPharma Credit's Insider Ownership of 0.08 % can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for an Asset Management company?
A good Insider Ownership depends on the Asset Management industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on BioPharma Credit and its competitors. BioPharma Credit's current Insider Ownership is 0.08 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.96, compared to a current price of $0.97 — trading 0.8% above its estimated fair value. The current Insider Ownership is 0.08 %. BioPharma Credit's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current Insider Ownership is 0.08 % as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?

Based on GuruFocus' analysis, BioPharma Credit stock appears to be overvalued. The current stock price of $0.97 is trading 0.8% above its estimated GF Value™ of $0.96. GuruFocus considers BioPharma Credit to be Fairly Valued.

Key valuation signals for LSE:BPCR:

  • Insider Ownership: 0.08 %
  • GF Value™: $0.96 vs. price of $0.97 (0.8% above fair value)
  • GF Score™: 51/100 with 2 warning signs

No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioPharma Credit Business Description

Address c/o MUFG Corporate Governance Limited, 51 Lime Street, 19th Floor, London, GBR, EC3M 7DQ
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
51GF Score

Get the complete analysis for LSE:BPCR

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.97
Price
$0.96
GF Value